Complications of surgery for gastro-entero-pancreatic neuroendocrine neoplasias

被引:17
作者
Albers, Max B. [1 ,2 ,3 ]
Almquist, Martin [1 ,2 ]
Bergenfelz, Anders [1 ,2 ]
Nordenstrom, Erik [1 ,2 ]
机构
[1] Lund Univ, Skane Univ Hosp, Dept Surg, Lund, Sweden
[2] Lund Univ, Skane Univ Hosp, Dept Clin Sci, Lund, Sweden
[3] Philipps Univ Marburg, Dept Visceral Thorac & Vasc Surg, Marburg, Germany
关键词
Neuroendocrine neoplasia; Perioperative complications; Surgery; Gastro-entero-pancreatic system; Small intestine; Pancreas; ENETS CONSENSUS GUIDELINES; POSTOPERATIVE COMPLICATIONS; TUMORS; MANAGEMENT; UPDATE; RESECTION; CLASSIFICATION; MORTALITY; PROPOSAL; OUTCOMES;
D O I
10.1007/s00423-020-01869-0
中图分类号
R61 [外科手术学];
学科分类号
摘要
Purpose Surgery is recommended for most patients with gastro-entero-pancreatic neuroendocrine neoplasias (GEP-NENs). Rates of complications and perioperative mortality have been reported in few mostly retrospective single-center series, but there has been no detailed analysis on risk factors for perioperative complications and mortality to date. Methods Data of patients with GEP-NENs operated between January 2015 and September 2018 were retrieved from EUROCRINE (c), a European online endocrine surgical quality registry, and analyzed regarding rate and risk factors of surgical complications. Risk factors were assessed by logistic regression. Results Some 376 patients (211 female, 167 male; age median 63, range 15-89 years) were included. Most NENs were located in the small intestine (SI) (n = 132) or pancreas (n = 111), the rest in the stomach (n = 34), duodenum (n = 30), appendix (n = 30), colon, and rectum (n = 22), or with unknown primary (n = 15). Of the tumors, 320 (85.1%) were well or moderately differentiated, and 147 (39.1%) of the patients had distant metastases at the time of operation. Severe complications (Dindo-Clavien >= 3) occurred in 56 (14.9%) patients, and 4 (1.1%) patients died perioperatively. Severe complications were more frequent in surgery for duodenopancreatic NENs (n = 31; 22.0%) compared with SI-NENs (n = 15; 11.4%) (p = 0.014), in patients with lymph node metastases operated with curative aim of surgery (n = 24; 21.4%) versus non-metastasized tumors or palliative surgery (n = 32; 12.1%) (p = 0.020), and in functioning tumors (n = 20; 23.0%) versus non-functioning tumors (n = 30; 13.5%) (p = 0.042). Complication rates were not significantly associated with tumor stage or grade. Conclusions Severe complications are frequent in GEP-NEN surgery. Besides duodenopancreatic tumor location, curative resection of nodal metastases and functioning tumors are risk factors for complications.
引用
收藏
页码:137 / 143
页数:7
相关论文
共 50 条
  • [11] Gastro-entero-pancreatic neuroendocrine neoplasia: The rules for non-operative management
    Panzuto, Francesco
    Massironi, Sara
    Partelli, Stefano
    Campana, Davide
    Rinzivillo, Maria
    Invernizzi, Pietro
    Andreasi, Valentina
    Lamberti, Giuseppe
    Falconi, Massimo
    SURGICAL ONCOLOGY-OXFORD, 2020, 35 : 141 - 148
  • [12] Indications for genetic study in gastro-entero-pancreatic and thoracic neuroendocrine tumors
    Araujo-Castro, Marta
    ENDOCRINOLOGIA DIABETES Y NUTRICION, 2023, 70 : 63 - 73
  • [13] Utility of histopathological revision in the management of gastro-entero-pancreatic neuroendocrine neoplasia
    Marasco, Matteo
    Magi, Ludovica
    Rogges, Evelina
    Dell'Unto, Elisabetta
    Rinzivillo, Maria
    Pilozzi, Emanuela
    Annibale, Bruno
    Panzuto, Francesco
    ENDOCRINE, 2023, 82 (02) : 435 - 441
  • [14] Factors Predicting Prognosis in Metastatic Grade 1 Gastro-entero-pancreatic Neuroendocrine Tumors
    Pandrowala, Saneya A.
    Kapoor, Deeksha
    Kunte, Aditya
    Chopde, Amit
    Puranik, Ameya
    Dev, Indraja Devidas
    Parghane, Rahul
    Basu, Sandip
    Ramaswamy, Anant
    Ostwal, Vikas
    Chaudhari, Vikram A.
    Bhandare, Manish S.
    Shrikhande, Shailesh V.
    JOURNAL OF GASTROINTESTINAL CANCER, 2024, 55 (03) : 1220 - 1228
  • [15] Neuroendocrine tumors of the gastro-entero-pancreatic system:: The role of early diagnosis, genetic testing and preventive surgery
    Plöckinger, U
    Wiedenmann, B
    DIGESTIVE DISEASES, 2002, 20 (01) : 49 - 60
  • [16] Molecular Pathology of Well-Differentiated Gastro-entero-pancreatic Neuroendocrine Tumors
    Asa, Sylvia L.
    La Rosa, Stefano
    Basturk, Olca
    Adsay, Volkan
    Minnetti, Marianna
    Grossman, Ashley B.
    ENDOCRINE PATHOLOGY, 2021, 32 (01) : 169 - 191
  • [17] Feasibility of Radio-Guided Surgery with 68Gallium-DOTATATE in Patients with Gastro-Entero-Pancreatic Neuroendocrine Tumors
    Sadowski, Samira M.
    Millo, Corina
    Neychev, Vladimir
    Aufforth, Rachel
    Keutgen, Xavier
    Glanville, Joanne
    Alimchandani, Meghna
    Nilubol, Naris
    Herscovitch, Peter
    Quezado, Martha
    Kebebew, Electron
    ANNALS OF SURGICAL ONCOLOGY, 2015, 22 : S676 - S682
  • [18] Microsatellite instability and allelic losses in neuroendocrine tumors of the gastro-entero-pancreatic system
    Ghimenti, C
    Lonobile, A
    Campani, D
    Bevilacqua, G
    Caligo, MA
    INTERNATIONAL JOURNAL OF ONCOLOGY, 1999, 15 (02) : 361 - 366
  • [19] Surgery in Patients with Gastro-Entero-Pancreatic Neuroendocrine Carcinomas, Neuroendocrine Tumors G3 and High Grade Mixed Neuroendocrine-Non-Neuroendocrine Neoplasms
    Holmager, Pernille
    Langer, Seppo W.
    Kjaer, Andreas
    Ringholm, Lene
    Garbyal, Rajendra Singh
    Pommergaard, Hans-Christian
    Hansen, Carsten Falnaes
    Federspiel, Birgitte
    Andreassen, Mikkel
    Knigge, Ulrich
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2022, 23 (06) : 806 - 817
  • [20] Endoscopic Management of Gastro-Entero-Pancreatic Neuroendocrine Tumours: An Overview of Proposed Resection and Ablation Techniques
    Chacchi-Cahuin, Rocio
    Despott, Edward J.
    Lazaridis, Nikolaos
    Rimondi, Alessandro
    Fusai, Giuseppe Kito
    Mandair, Dalvinder
    Anderloni, Andrea
    Sciola, Valentina
    Caplin, Martyn
    Toumpanakis, Christos
    Murino, Alberto
    CANCERS, 2024, 16 (02)